novo nordisk glp 1 drugs Novo, Lilly buoyed by fast-growing GLP-1 drug sales The FDA has approved the

Current evidence suggests a neutral effect overall, although some studies indicate potential benefits in reducing risk

The medication labels for Ozempic and Mounjaro, which are prescribed to help people with type 2 diabetes manage blood sugar, specifically say they are not intended for use with type 1

13 While GLP-1 agonist-induced weight loss can decrease mechanical load through the musculoskeletal system and improve aspects of physical function, the resulting negative effects on tendons, impaired muscle function, and joint degradation can persist after a healthy weight has been achieved

SGLT2 inhibitors (e.g., Jardiance, Farxiga): May aid in modest weight loss by helping eliminate excess glucose

The above meta-analyses comprised all clinical trials we could retrieve with our search 52,183,184,185,186,189,191,196,197,198,199,200